10943 related articles for article (PubMed ID: 15609895)
21. Melanocortin-1 receptor: loss of function mutations and skin cancer.
Mumm CD; Draznin M
Dermatol Online J; 2006 Sep; 12(5):13. PubMed ID: 16962028
[TBL] [Abstract][Full Text] [Related]
22. Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.
Nagore E; Montoro A; García-Casado Z; Botella-Estrada R; Insa A; Lluch A; López-Guerrero JA; Guillén C
Melanoma Res; 2009 Aug; 19(4):211-4. PubMed ID: 19571771
[TBL] [Abstract][Full Text] [Related]
23. A novel L94Q mutation in the CDKN2A gene in a melanoma kindred.
Avbelj M; Hocevar M; Trebusak-Podkrajsek K; Krzisnik C; Battelino T
Melanoma Res; 2003 Dec; 13(6):567-70. PubMed ID: 14646619
[TBL] [Abstract][Full Text] [Related]
24. Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes.
Chaudru V; Lo MT; Lesueur F; Marian C; Mohamdi H; Laud K; Barrois M; Chompret A; Avril MF; Demenais F; Bressac-de Paillerets B
Fam Cancer; 2009; 8(4):371-7. PubMed ID: 19484507
[TBL] [Abstract][Full Text] [Related]
25. DNA repair gene polymorphisms and genetic predisposition to cutaneous melanoma.
Povey JE; Darakhshan F; Robertson K; Bisset Y; Mekky M; Rees J; Doherty V; Kavanagh G; Anderson N; Campbell H; MacKie RM; Melton DW
Carcinogenesis; 2007 May; 28(5):1087-93. PubMed ID: 17210993
[TBL] [Abstract][Full Text] [Related]
26. [Genotypic hypervariability of melanoma: a therapeutic challenge].
Dalle S; Martin-Denavit T; Thomas L
Med Sci (Paris); 2006 Feb; 22(2):178-82. PubMed ID: 16457759
[TBL] [Abstract][Full Text] [Related]
27. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
[TBL] [Abstract][Full Text] [Related]
28. Molecular and genetic mechanisms in melanoma.
Gruber F; Kastelan M; Brajac I; Saftić M; Peharda V; Cabrijan L; Stanić Zgombić Z; Simonić E
Coll Antropol; 2008 Oct; 32 Suppl 2():147-52. PubMed ID: 19138018
[TBL] [Abstract][Full Text] [Related]
29. Melanoma susceptibility genes and risk assessment.
Marzuka-Alcalá A; Gabree MJ; Tsao H
Methods Mol Biol; 2014; 1102():381-93. PubMed ID: 24258989
[TBL] [Abstract][Full Text] [Related]
30. Role of the CDKN2A locus in patients with multiple primary melanomas.
Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M
J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic variation in familial melanoma: consequences for predictive DNA testing.
Bergman W; Gruis NA
Arch Dermatol; 2007 Apr; 143(4):525-6. PubMed ID: 17438187
[No Abstract] [Full Text] [Related]
32. CYP2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors.
Gomes L; Lemos MC; Paiva I; Ribeiro C; Carvalheiro M; Regateiro FJ
Acta Med Port; 2005; 18(5):339-43. PubMed ID: 16611538
[TBL] [Abstract][Full Text] [Related]
33. Genetic testing for melanoma predisposition: current challenges.
Gerstenblith MR; Goldstein AM; Tucker MA; Fraser MC
Cancer Nurs; 2007; 30(6):452-9; quiz 462-3. PubMed ID: 18025917
[TBL] [Abstract][Full Text] [Related]
34. The genetics of susceptibility to cutaneous melanoma.
Newton Bishop JA; Bishop DT
Drugs Today (Barc); 2005 Mar; 41(3):193-203. PubMed ID: 15883616
[TBL] [Abstract][Full Text] [Related]
35. Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma.
Jannot AS; Meziani R; Bertrand G; Gérard B; Descamps V; Archimbaud A; Picard C; Ollivaud L; Basset-Seguin N; Kerob D; Lanternier G; Lebbe C; Saiag P; Crickx B; Clerget-Darpoux F; Grandchamp B; Soufir N; Melan-Cohort
Eur J Hum Genet; 2005 Aug; 13(8):913-20. PubMed ID: 15889046
[TBL] [Abstract][Full Text] [Related]
36. New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment.
Kannengiesser C; Dalle S; Leccia MT; Avril MF; Bonadona V; Chompret A; Lasset C; Leroux D; Thomas L; Lesueur F; Lenoir G; Sarasin A; Bressac-de Paillerets B
Genes Chromosomes Cancer; 2007 Aug; 46(8):751-60. PubMed ID: 17492760
[TBL] [Abstract][Full Text] [Related]
37. The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy.
Gensini F; Sestini R; Piazzini M; Vignoli M; Chiarugi A; Brandani P; Ghiorzo P; Salvini C; Borgognoni L; Palli D; Bianchi-Scarrà G; Carli P; Genuardi M
Melanoma Res; 2007 Dec; 17(6):387-92. PubMed ID: 17992122
[TBL] [Abstract][Full Text] [Related]
38. Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32.
Jönsson G; Bendahl PO; Sandberg T; Kurbasic A; Staaf J; Sunde L; Crüger DG; Ingvar C; Olsson H; Borg A
J Natl Cancer Inst; 2005 Sep; 97(18):1377-82. PubMed ID: 16174859
[TBL] [Abstract][Full Text] [Related]
39. A common variant of CDKN2A (p16) predisposes to breast cancer.
Debniak T; Górski B; Huzarski T; Byrski T; Cybulski C; Mackiewicz A; Gozdecka-Grodecka S; Gronwald J; Kowalska E; Haus O; Grzybowska E; Stawicka M; Swiec M; Urbański K; Niepsuj S; Waśko B; Góźdź S; Wandzel P; Szczylik C; Surdyka D; Rozmiarek A; Zambrano O; Posmyk M; Narod SA; Lubinski J
J Med Genet; 2005 Oct; 42(10):763-5. PubMed ID: 15879498
[TBL] [Abstract][Full Text] [Related]
40. CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families.
Lang J; Boxer M; MacKie RM
Br J Dermatol; 2005 Dec; 153(6):1121-5. PubMed ID: 16307646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
